Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Fulcrum Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analysts, with varying recommendations from eight research firms including one strong buy and one sell rating.
• Recent upgrades from analysts include a target price increase by Leerink Partners from $4.00 to $12.00 and by Piper Sandler from $6.00 to $9.00, indicating strong bullish sentiment.
• Institutional investors own approximately 89.83% of Fulcrum Therapeutics, with significant increases in holdings by firms such as Vanguard and Algert Global in recent quarters.

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $7.57.

Several equities research analysts have recently weighed in on FULC shares. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective for the company in a research report on Thursday, May 15th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. HC Wainwright upgraded shares of Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $4.00 to $12.00 in a research report on Tuesday. Royal Bank Of Canada increased their price objective on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a "sector perform" rating in a research report on Wednesday. Finally, Piper Sandler reiterated an "overweight" rating and set a $9.00 price objective (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th.

Institutional Trading of Fulcrum Therapeutics

Several hedge funds have recently added to or reduced their stakes in FULC. Nantahala Capital Management LLC grew its stake in Fulcrum Therapeutics by 0.9% in the 1st quarter. Nantahala Capital Management LLC now owns 4,822,693 shares of the company's stock worth $13,889,000 after buying an additional 42,985 shares in the last quarter. Suvretta Capital Management LLC grew its stake in Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after buying an additional 2,155,675 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Fulcrum Therapeutics by 50.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company's stock worth $14,100,000 after buying an additional 1,000,000 shares in the last quarter. Woodline Partners LP grew its stake in Fulcrum Therapeutics by 110.3% in the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after buying an additional 739,713 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Fulcrum Therapeutics by 25.1% in the 4th quarter. Northern Trust Corp now owns 710,321 shares of the company's stock worth $3,339,000 after buying an additional 142,578 shares in the last quarter. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock traded down $0.22 on Monday, reaching $6.68. 310,708 shares of the stock were exchanged, compared to its average volume of 582,483. The firm has a market cap of $360.59 million, a PE ratio of -5.48 and a beta of 2.37. The firm's 50 day moving average is $7.15 and its 200-day moving average is $4.95. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. On average, equities research analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.